130 results
Page 3 of 7
6-K
EX-99.1
ha57a4xx3ffn761r5r4
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.3
2gcjs
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.2
rulrekjb j0e9
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
2jn7a43
7 Apr 22
Current report (foreign)
4:01pm
6-K
EX-99.1
1uvdgvnww0
24 Mar 22
InflaRx Reports Full Year 2021 Financial and Operating Results
8:40am
6-K
EX-99.1
yxivspl odav
16 Feb 22
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
7:30am
6-K
EX-99.2
so1au hteas9rzkxq
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
6-K
EX-99.2
vwece rbq
15 Nov 21
Current report (foreign)
7:36am
6-K
EX-99.1
6hzg82p3ahjt9
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.2
bn3 7anvzbx
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.2
uh7m50kcm x8l4g1
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am
6-K
EX-99.1
g4sg0l6kq4zmm afa
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.3
e27q03bq fim2sx8xo
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.2
971r9pv6 ls6s
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
13bl6
8 Jun 21
Current report (foreign)
7:30am